Maxim Group Downgrades Akari Therapeutics to Hold

Akari Therapeutics Plc Sponsored ADR +4.12%

Akari Therapeutics Plc Sponsored ADR

AKTX

6.18

+4.12%

Maxim Group analyst Jason McCarthy downgrades Akari Therapeutics (NASDAQ: AKTX) from Buy to Hold.